New radiation drug shows promise for Tough-to-Treat breast cancer
NCT ID NCT06590857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is safe and can shrink tumors. About 16 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Facility
Phoenix, Arizona, 85054, United States
-
Research Facility
Irvine, California, 92618, United States
-
Research Facility
San Diego, California, 92093, United States
-
Research Facility
Santa Monica, California, 90404, United States
-
Research Facility
Longmont, Colorado, 80504, United States
-
Research Facility
Jacksonville, Florida, 32224, United States
-
Research Facility
Atlanta, Georgia, 30322, United States
-
Research Facility
Indianapolis, Indiana, 46202, United States
-
Research Facility
Boston, Massachusetts, 02215, United States
-
Research Facility
Detroit, Michigan, 48202, United States
-
Research Facility
Rochester, Minnesota, 55905, United States
-
Research Facility
St Louis, Missouri, 63130, United States
-
Research Facility
Omaha, Nebraska, 68124, United States
-
Research Facility
Albuquerque, New Mexico, 87109, United States
-
Research Facility
Buffalo, New York, 14203, United States
-
Research Facility
New York, New York, 10016, United States
-
Research Facility
New York, New York, 10021, United States
-
Research Facility
Cleveland, Ohio, 44195, United States
-
Research Facility
Philadelphia, Pennsylvania, 19104, United States
-
Research Facility
Pittsburgh, Pennsylvania, 15213, United States
-
Research Facility
Dallas, Texas, 75246, United States
-
Research Facility
Houston, Texas, 77024, United States
-
Research Facility
Salt Lake City, Utah, 84132, United States
-
Research Facility
Norfolk, Virginia, 23502, United States
-
Research Facility
Seattle, Washington, 98109, United States
-
Research Facility
Victoria, British Columbia, V8R 6V5, Canada
-
Research Facility
Toronto, Ontario, M4N 3M5, Canada
-
Research Facility
Toronto, Ontario, M5G 2M9, Canada
-
Research Facility
Québec, Quebec, G1S 4L8, Canada
-
Research Facility
Seoul, Seoul, 03080, South Korea
-
Research Facility
Seoul, Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Could a personal coach at home boost energy for cancer patients?